Status of minimal residual disease testing in childhood haematological malignancies.

British Journal of Haematology
Dario Campana

Abstract

In children with acute leukaemia, measurements of minimal residual disease (MRD) provide unique information on treatment response and have become a crucial component of contemporary treatment protocols. In acute lymphoblastic leukaemia (ALL), the most useful MRD assays are based on polymerase chain reaction (PCR) amplification of antigen-receptor genes, and on flow cytometric detection of abnormal immunophenotypes. The latter is the only MRD assay available for most patients with acute myeloid leukaemia (AML). PCR amplification of chromosomal breakpoints and fusion transcripts can also be used to track MRD in a minority of patients with ALL or AML. Because of the strong correlation between MRD levels and risk of relapse, several ongoing regimens include treatment intensification for children with higher MRD. Treatment de-intensification for patients with early MRD clearance is also being tested. In addition to their direct clinical application, MRD measurements can be used to better understand the molecular and cellular mechanisms of drug resistance in vivo. The identification of new markers of leukaemia and the use of increasingly sophisticated technologies for detection of rare cells should further facilitate routine monitori...Continue Reading

References

Oct 28, 1993·The New England Journal of Medicine·G K RiveraW M Crist
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P G SteinherzW A Bleyer
Dec 31, 1997·British Journal of Haematology·M J BriscoA A Morley
Aug 10, 1999·Cytometry·D Campana, E Coustan-Smith
Mar 6, 2002·Blood·Michael N DworzakUNKNOWN Austrian Berlin-Frankfurt-Münster Study Group
Mar 22, 2002·The Lancet Oncology·T SzczepańskiJ J van Dongen
Aug 30, 2002·British Journal of Haematology·Tim Eden
Jun 6, 2003·British Journal of Haematology·Dario Campana
Jun 26, 2003·British Journal of Haematology·Nick GouldenJacques Van Dongen
Oct 9, 2003·British Journal of Haematology·Elaine Coustan-SmithDario Campana
May 27, 2004·JAMA : the Journal of the American Medical Association·Scott C HowardFrancisco Pedrosa
May 27, 2005·The New England Journal of Medicine·Raul C Ribeiro, Ching-Hon Pui

❮ Previous
Next ❯

Citations

May 15, 2010·Current Hematologic Malignancy Reports·Dario Campana
Dec 23, 2008·Seminars in Hematology·Dario Campana
Jun 9, 2009·British Journal of Haematology·Rosemary SuttonUNKNOWN Australian and New Zealand Children's Oncology Group
Sep 13, 2012·British Journal of Haematology·Jeffrey E Rubnitz, Hiroto Inaba
Jun 4, 2011·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Cherry GreinerIrene Georgakoudi
Jun 13, 2013·Cytometry. Part B, Clinical Cytometry·Giuseppe GaipaDario Campana
Aug 5, 2011·British Journal of Haematology·Giovanni CazzanigaAndrea Biondi
Jul 12, 2011·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Cherry GreinerIrene Georgakoudi
Oct 5, 2010·Hematology/oncology and Stem Cell Therapy·Chumphorn BanklauSamart Pakakasama
Aug 27, 2019·Frontiers in Oncology·Irene Della StarzaRobin Foà

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

The New England Journal of Medicine
Ching-Hon Pui, W E Evans
The New England Journal of Medicine
Ching-Hon PuiJ R Downing
Cell
Peter A Jones, Stephen B Baylin
© 2022 Meta ULC. All rights reserved